CCL2 expression has also been found to be increased in paclitaxel resistant cell lines and in the serum of ovarian cancer patients following paclitaxel treatment (Duan et al, 1999; Penson et al, 2000). The gene discussed is CCL2; the disease is ovarian carcinoma.